Skip to main content
    X

    X4 Pharmaceuticals Inc (XFOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.09
    +0.26 (+9.19%)

    Market Cap: $288.98M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    X4 Pharmaceuticals Inc (XFOR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    X4 Pharmaceuticals (XFOR) trades at 23.6x sales and 2.8x book value. Its P/B of 2.8x is above its 5-year median of 2.7x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales23.6x
    Price to book2.8x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B2.8x2.7xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 6 of the 9 year ends shown that have a P/S, its P/S ranged from 0.9x in 2025 to 190.3x in 2022. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$4.000.9x2.4x
    2024$22.0358.0x6.7x
    2023$25.1854.5x3.3x
    2022$29.82190.3x1.4x
    2021$68.77N/A1.0x
    2020$193.0950.2x1.8x
    2019$321.325.3x1.4x
    2018$417.93N/A33.2x
    2017$2,298.64N/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About XFOR

    What is XFOR's price to sales ratio?

    X4 Pharmaceuticals has a price to sales ratio of 23.6x.